| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.PNPBP.2003.09.033 |
| P698 | PubMed publication ID | 14687871 |
| P50 | author | Istvan Bitter | Q42305895 |
| P2093 | author name string | Gabor Kovacs | |
| Stephen Metcalfe | |||
| Alan Breier | |||
| János Füredi | |||
| Peter D Feldman | |||
| Zoltan Janka | |||
| Martin R K Dossenbach | |||
| Csaba M Banki | |||
| Shlomo Brook | |||
| Carlo A Gagiano | |||
| György Bartko | |||
| Olanzapine HGCK Study Group | |||
| P433 | issue | 1 | |
| P921 | main subject | schizophrenia | Q41112 |
| P304 | page(s) | 173-180 | |
| P577 | publication date | 2004-01-01 | |
| P1433 | published in | Progress in Neuro-Psychopharmacology & Biological Psychiatry | Q15616665 |
| P1476 | title | Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia | |
| P478 | volume | 28 |
| Q90353605 | A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future |
| Q37998840 | A quantitative review of the profile and time course of symptom change in schizophrenia treated with clozapine. |
| Q34661499 | Almost all antipsychotics result in weight gain: a meta-analysis |
| Q37188995 | Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal |
| Q28728401 | Changes in body weight and psychotropic drugs: a systematic synthesis of the literature |
| Q64882655 | Closure beyond clozapine: successfully averting rebound symptoms in a patient with schizoaffective disorder and agranulocytosis. |
| Q38706468 | Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis |
| Q38026886 | Clozapine for the treatment of schizophrenia |
| Q24236422 | Clozapine versus other atypical antipsychotics for schizophrenia |
| Q24240931 | Clozapine versus typical neuroleptic medication for schizophrenia |
| Q38042478 | Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis |
| Q37227479 | Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features |
| Q102210892 | Effectiveness of antipsychotic drugs in schizophrenia: a 10-year retrospective study in a Korean tertiary hospital |
| Q38068636 | Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses |
| Q38297089 | Glucose-insulin homeostasis, lipid profiles and GH-IGF-IGFBP axis in clozapine-treated schizophrenic obesity versus non-psychiatric obesity |
| Q91442157 | Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis |
| Q97522429 | Initiating clozapine treatment service and characteristics of clozapine-treated patients in a general hospital in Addis Ababa, Ethiopia |
| Q37546091 | Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction? |
| Q24244031 | Olanzapine for schizophrenia |
| Q24236545 | Olanzapine versus other atypical antipsychotics for schizophrenia |
| Q34331847 | Ranitidine, metformin, and topiramate: managing weight gain in a clozapine-treated patient with schizoaffective disorder |
| Q30383064 | Reversal of evoked gamma oscillation deficits is predictive of antipsychotic activity with a unique profile for clozapine. |
| Q48370703 | Role of the simultaneous enhancement of NMDA and dopamine D1 receptor-mediated neurotransmission in the effects of clozapine on phencyclidine-induced acute increases in glutamate levels in the rat medial prefrontal cortex |
| Q50779681 | Safety and efficacy of olanzapine monotherapy in treatment-resistant bipolar mania: a 12-week open-label study. |
| Q37061154 | Strong Treatment Response and High Maintenance Rates of Clozapine in Childhood-Onset Schizophrenia |
| Q33566124 | The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements |
| Q47642128 | The Black Book of Psychotropic Dosing and Monitoring |
| Q37693165 | Time to 'get real': preliminary insights into the long-term management of schizophrenia |
| Q21260279 | Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia |
| Q39029626 | Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology |
| Q34640811 | World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance |
Search more.